Nestlé invests a further 200 million dollars in food allergies firm | Progresiv
Nestlé Health Science (NHSc), a wholly-owned subsidiary of Nestlé, is making a further equity investment of 200 million dollars in Aimmune Therapeutics, a California-based biopharmaceutical company developing and commercialising treatment for potentially life-threatening food allergies. 
NHSc’s total investment to date in the company is 473 million dollars, bringing its total equity ownership to 25.6%.
Last week, the FDA approved the first-ever treatment for peanut allergies in young patients, Aimmune Therapeutics’s Palforzia.
“We first invested in Aimmune in 2016 and have been closely involved since then,” said Greg Behar, NHSc CEO and Aimmune Therapeutics Board Member.
“Their research and development approach is fully aligned with our mission of empowering healthier lives through science-based nutritional solutions. We expect Aimmune’s Palforzia, the first medication approved by the United States Food and Drug Administration for food allergies in children and teens, to change the landscape of food allergy treatment and look forward to even more innovations.”
Investing in food allergy therapies is an extension of NHSc’s current pediatric food allergy portfolio. This includes its products for babies and young children with Cow’s Milk Protein Allergy and its investment in Before Brands, which makes SpoonfulOne, a nutrition-based, early childhood, food allergy-prevention product. (www.kamcity.com)
